Skip to main content
Clinical Trials/CTRI/2018/03/012410
CTRI/2018/03/012410
Completed
未知

A clinical study to evaluate the efficacy and safety of Curcumin supplementation (CurQfen - The enhanced bio available formulation of curcumin) on Dementia patients having Mild to Moderate decline in Locomotor activities and impairment in Learning/Memory

Akay Flavours and Aromatics Private Limited0 sites48 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: null- Dementia
Sponsor
Akay Flavours and Aromatics Private Limited
Enrollment
48
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
February 22, 2018
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Akay Flavours and Aromatics Private Limited

Eligibility Criteria

Inclusion Criteria

  • 1\. Age 55\-75 Years ( Both Inclusive)
  • 2\.Male and Female Subjects
  • 3\.Patients with a MMSE Score Less than 26 and More than 14 (Both are Inclusive)
  • 4\.Must have a caregiver to attend the study visit.
  • 5\.Informed consent from Subject and Legally acceptable Representative\-LAR( LAR can be Spouse/Parent/Son/Daughter/Guardian/Person Having charge or any other legally acceptable Representative)

Exclusion Criteria

  • 1\.Severe Memory Loss
  • 3\.Psychiatric illness
  • 4\.Subjects who are under the treatment with anti Inflammatory Drugs
  • 5\.Objection from family members or any other close relatives or Legally acceptable representatives
  • 6\.If the participation in the study cause any harm to possible benefits to the patients, including Insurance benefits.
  • 7\.Objection from the Physician, under whom, current treatment is going on.
  • 8\.Patients, who are in the Clinicians judgment, are like to be placed in a nursing home, within next 6 months
  • 9\.Any condition that in Opinion of the Investigator, does not justify the Subjectsâ?? participation in the study.

Outcomes

Primary Outcomes

Not specified

Similar Trials